Ishii, Miho
Ito, Wakako
Karube, Yuki
Ogawa, Yuko
Tagawa, Anna
Maeda, Shunta
Sato, Hideki
Takahashi, Toru
Inomata, Natsumi
Narisawa, Hajime
Takaesu, Yoshikazu
Watanabe, Koichiro
Okajima, Isa http://orcid.org/0000-0003-3494-4328
Article History
Received: 28 June 2021
Accepted: 21 October 2021
First Online: 10 November 2021
Declarations
:
: The authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai.
: This study was approved by the ethics committee of Institute of Neuropsychiatry. All participants provided written informed consent (Trial Registration No. UMIN000024461; umin.ac.jp/ctr).